Market by Type, Condition, Therapeutic Type, Delivery Method, Channel, and Country Outlook | Forecast 2023-2030
Triton’s research report infers that the Middle East and Africa ophthalmic drugs market is estimated to grow with a CAGR of 7.17% in revenue during the 2023-2030 forecasted years.
Report scope can be customized per your requirements - Request Free Sample Report
The countries analyzed in this region include:
•        United Arab Emirates
•        Turkey
•        Saudi
Arabia
•        Rest
of the Middle East & Africa
The Middle East and
African ophthalmic drugs market benefits from
innovations that help to reshape and improve eye care services. Added to that
are the strategic collaborations between healthcare systems and pharmaceutical
companies, which facilitate new delivery channels for targeted treatment. The
ophthalmic drug delivery system sets a wider approach to cater to the rising
middle-class population, thereby driving the market demand for ophthalmic
drugs.
The United Arab Emirates (UAE) captures the majority share in the ophthalmic
drugs market. This
growth is primarily driven by the evolving
healthcare landscape, the rise in ocular conditions, cataracts, and
pharmaceutical inventions. The country requires tailored treatment for specific
eye ailments to ensure optimal eye health and reduce vision impairment. Also,
the elderly population and their age-related eye disorders continue to boost
the demand for ophthalmic drugs. New delivery methods, timely eye-checkups and
innovations in the drug formulations also contribute heavily to the market
growth.
The ophthalmic drugs market in Turkey is regulated by
the Turkish Medicines and Medical Devices Agency (TITCK), which ensures safe
manufacturing and high quality of ophthalmic drug products. The country also
presents an opportunity for new entrants to provide effective ophthalmic
treatments at affordable prices, thereby having a competitive edge. Additionally,
the rising awareness regarding age-related eye diseases influences the
healthcare sector. Thus, the ophthalmic drugs market has a huge potential to grow
in both urban and rural areas.
Anti-allergy
therapeutic drugs are specific medicines to cure allergic reactions. They are
formulated as eye drops, ointments, or ophthalmic solutions. Mast Cell Stabilizers,
Dual-Action Antihistamines, and Antihistamines are some widely used ophthalmic
drugs for treating redness, swelling, and itching in the eyes. The segments of the market consist of type, delivery method, therapeutic type,
condition, and channel. The therapeutic type segment includes
anti-allergy, anti-glaucoma, anti-infection, anti-inflammatory and
other therapeutic classes.
The companies in the reviewed market are Novartis AG, Accutome Inc, Bausch Health Companies Inc,
AbbVie Inc, Sun Pharmaceutical Industries Ltd, Johnson & Johnson, Thea Pharma Inc, Regeneron Pharmaceuticals Inc, Pfizer Inc,
and Genentech Inc.
Novartis
AG is a healthcare company that manufactures products like biosimilars,
surgical instruments, vision care products, generic medicines, and ophthalmic
pharmaceuticals. Headquartered in Basel, Switzerland, the company also operates
in the Middle East and Africa, Europe, Asia-Pacific, and America. It also
offers its products under Sandoz, Votrient, Alcon, Clear Care, AIR OPTIX,
DAILIES, Lucentis, and FreshLook brands.
KEY
DELIVERABLES OF THE REPORT:
â—ŹÂ Â Â Â Â
Market CAGR during the forecasting years 2023-2030
â—ŹÂ Â Â Â Â
Detailed data highlighting key insights, industry components, and
market strategies
â—ŹÂ Â Â Â Â
Comprehensive information and estimation of the ophthalmic
drugs
market revenue growth in the Middle East and Africa and its influence on the
parent market
â—ŹÂ Â Â Â Â
In-depth study of forthcoming trends in consumer behavioral
patterns
â—ŹÂ Â Â Â Â
A meticulous analysis of the competitive landscape, vendor
scorecard, and Porter’s Five Forces
â—ŹÂ Â Â Â Â
A wide-ranging study of factors that will challenge the Middle
East and Africa ophthalmic drugs market’s growth during the upcoming
years
Want to get specific insights? Our team of
analysts can customize this report based on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1.   MIDDLE
EAST AND AFRICA OPHTHALMIC DRUGS MARKET - SUMMARY
2.   INDUSTRY
OUTLOOK
2.1. TECHNOLOGY
SNAPSHOT
2.2. IMPACT
ANALYSIS ON THE OPHTHALMIC DRUGS MARKET
2.2.1. COVID-19
IMPACT ON THE OPHTHALMIC DRUGS MARKET
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. MARKET
MATURITY ANALYSIS
2.5. REGULATORY
FRAMEWORK
2.6. KEY
BUYING IMPACT ANALYSIS
2.7. KEY
MARKET STRATEGIES
2.7.1. COLLABORATIONS
2.7.2. PRODUCT
LAUNCHES
2.7.3. MERGERS
& ACQUISITIONS
2.8. MARKET
DRIVERS
2.8.1. AGING
POPULATION VULNERABLE TO EYE DISORDERS
2.8.2. PROGRESS
IN DRUG DELIVERY TECHNOLOGIES
2.8.3. ESCALATING
INCIDENCE OF OCULAR DISEASES
2.8.4. REIMBURSEMENT
POLICIES BY HEALTHCARE SYSTEMS
2.9. MARKET
CHALLENGES
2.9.1. CHALLENGING
TIMELINES FOR PRODUCT APPROVAL
2.9.2. ADVERSE
EFFECTS ASSOCIATED WITH OPHTHALMIC DRUG USAGE
2.10. MARKET
OPPORTUNITIES
2.10.1. SURGE
IN INTEREST REGARDING TOPICALLY ADMINISTERED OPHTHALMIC DRUGS
2.10.2. INCREASE
IN APPROVALS FOR INNOVATIVE OPHTHALMIC THERAPIES
2.11. ANALYST
PERSPECTIVE
3.   MIDDLE
EAST AND AFRICA OPHTHALMIC DRUGS MARKET – BY TYPE
3.1. PRESCRIPTION
DRUGS
3.2. OVER-THE-COUNTER
DRUGS
4.   MIDDLE
EAST AND AFRICA OPHTHALMIC DRUGS MARKET – BY CONDITION
4.1. DRY
EYE
4.2. GLAUCOMA
4.3. INFECTION/INFLAMMATION/ALLERGIES
4.4. RETINAL
DISORDER
4.4.1. WET-AGE
RELATED MACULAR DEGENERATION
4.4.2. DRY-AGE
RELATED MACULAR DEGENERATION
4.4.3. DIABETIC
RETINOPATHY
4.4.4. OTHER
RETINAL DISORDERS
4.5. OTHER
CONDITIONS
5.   MIDDLE
EAST AND AFRICA OPHTHALMIC DRUGS MARKET – BY THERAPEUTIC TYPE
5.1. ANTI-GLAUCOMA
5.2. ANTI-INFECTION
5.3. ANTI-INFLAMMATORY
5.4. ANTI-ALLERGY
5.5. OTHER
THERAPEUTIC TYPES
6.   MIDDLE
EAST AND AFRICA OPHTHALMIC DRUGS MARKET – BY DELIVERY METHOD
6.1. GELS
6.2. EYE SOLUTIONS
& SUSPENSIONS
6.3. CAPSULES
& TABLETS
6.4. EYE
DROPS
6.5. OINTMENTS
7.   MIDDLE
EAST AND AFRICA OPHTHALMIC DRUGS MARKET – BY CHANNEL
7.1. HOSPITAL
PHARMACIES
7.2. DRUG
STORES
7.3. ONLINE
PHARMACIES
7.4. OTHER
CHANNELS
8.   MIDDLE
EAST AND AFRICA OPHTHALMIC DRUGS MARKET – COUNTRY OUTLOOK
8.1. UNITED
ARAB EMIRATES
8.1.1. UNITED
ARAB EMIRATES OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.2. TURKEY
8.2.1. TURKEY
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.3. SAUDI
ARABIA
8.3.1. SAUDI
ARABIA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.4. SOUTH
AFRICA
8.4.1. SOUTH
AFRICA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.5. REST
OF MIDDLE EAST & AFRICA
8.5.1. REST
OF MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
9.   COMPETITIVE
LANDSCAPE
9.1. ABBVIE
INC
9.1.1. OVERVIEW
9.1.2. PRODUCT
PORTFOLIO
9.1.3. KEY
STRENGTHS
9.1.4. KEY
CHALLENGES
9.2. BAUSCH
HEALTH COMPANIES INC
9.2.1. OVERVIEW
9.2.2. PRODUCT
PORTFOLIO
9.2.3. KEY
STRENGTHS
9.2.4. KEY
CHALLENGES
9.3. JOHNSON
& JOHNSON
9.3.1. OVERVIEW
9.3.2. PRODUCT
PORTFOLIO
9.3.3. KEY
STRENGTHS
9.3.4. KEY
CHALLENGES
9.4. NOVARTIS
AG
9.4.1. OVERVIEW
9.4.2. PRODUCT
PORTFOLIO
9.4.3. KEY
STRENGTHS
9.4.4. KEY
CHALLENGES
9.5. REGENERON
PHARMACEUTICALS INC
9.5.1. OVERVIEW
9.5.2. PRODUCT
PORTFOLIO
9.5.3. KEY
STRENGTHS
9.5.4. KEY
CHALLENGES
9.6. SUN
PHARMACEUTICAL INDUSTRIES LTD
9.6.1. OVERVIEW
9.6.2. PRODUCT
PORTFOLIO
9.6.3. KEY
STRENGTHS
9.6.4. KEY
CHALLENGES
9.7. ACCUTOME
INC
9.7.1. OVERVIEW
9.7.2. PRODUCT
PORTFOLIO
9.7.3. KEY
STRENGTHS
9.7.4. KEY
CHALLENGES
9.8. GENENTECH
INC
9.8.1. OVERVIEW
9.8.2. PRODUCT
PORTFOLIO
9.8.3. KEY
STRENGTHS
9.8.4. KEY CHALLENGES
9.9. THEA
PHARMA INC
9.9.1. OVERVIEW
9.9.2. PRODUCT
PORTFOLIO
9.9.3. KEY
STRENGTHS
9.9.4. KEY
CHALLENGES
9.10. PFIZER
INC
9.10.1. OVERVIEW
9.10.2. PRODUCT
PORTFOLIO
9.10.3. KEY
STRENGTHS
9.10.4. KEY
CHALLENGES
10. RESEARCH
METHODOLOGY & SCOPE
10.1. RESEARCH
SCOPE & DELIVERABLES
10.2. SOURCES
OF DATA
10.3. RESEARCH
METHODOLOGY
TABLE 1: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY COUNTRY,
2023-2030 (IN $ MILLION)
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: LIST OF COLLABORATIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF MERGERS & ACQUISITIONS
TABLE 6: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY COUNTRY
OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE 7: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY TYPE,
2023-2030 (IN $ MILLION)
TABLE 8: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY CONDITION,
2023-2030 (IN $ MILLION)
TABLE 9: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY RETINAL
DISORDER, 2023-2030 (IN $ MILLION)
TABLE 10: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC
TYPE, 2023-2030 (IN $ MILLION)
TABLE 11: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY DELIVERY
METHOD, 2023-2030 (IN $ MILLION)
TABLE 12: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY CHANNEL,
2023-2030 (IN $ MILLION)
FIGURE 1: TECHNOLOGY SNAPSHOT
FIGURE 2: MARKET MATURITY ANALYSIS
FIGURE 3: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2022
& 2030 (IN %)
FIGURE 4: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY PRESCRIPTION
DRUGS, 2023-2030 (IN $ MILLION)
FIGURE 5: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY
OVER-THE-COUNTER DRUGS, 2023-2030 (IN $ MILLION)
FIGURE 6: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY CONDITION,
2022 & 2030 (IN %)
FIGURE 7: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY DRY EYE,
2023-2030 (IN $ MILLION)
FIGURE 8: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY GLAUCOMA,
2023-2030 (IN $ MILLION)
FIGURE 9: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY
INFECTION/INFLAMMATION/ALLERGIES, 2023-2030 (IN $ MILLION)
FIGURE 10: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY RETINAL
DISORDER, 2023-2030 (IN $ MILLION)
FIGURE 11: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY RETINAL
DISORDER, 2022 & 2030 (IN %)
FIGURE 12: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY WET
AGE-RELATED MACULAR DEGENERATION, 2023-2030 (IN $ MILLION)
FIGURE 13: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY DRY
AGE-RELATED MACULAR DEGENERATION, 2023-2030 (IN $ MILLION)
FIGURE 14: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY DIABETIC
RETINOPATHY, 2023-2030 (IN $ MILLION)
FIGURE 15: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY OTHER
RETINAL DISORDERS, 2023-2030 (IN $ MILLION)
FIGURE 16: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY OTHER
CONDITIONS, 2023-2030 (IN $ MILLION)
FIGURE 17: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC
TYPE, 2022 & 2030 (IN %)
FIGURE 18: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY
ANTI-GLAUCOMA, 2023-2030 (IN $ MILLION)
FIGURE 19: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY
ANTI-INFECTION, 2023-2030 (IN $ MILLION)
FIGURE 20: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY
ANTI-INFLAMMATORY, 2023-2030 (IN $ MILLION)
FIGURE 21: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY
ANTI-ALLERGY, 2023-2030 (IN $ MILLION)
FIGURE 22: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY OTHER
THERAPEUTIC TYPES, 2023-2030 (IN $ MILLION)
FIGURE 23: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY DELIVERY
METHOD, 2022 & 2030 (IN %)
FIGURE 24: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY GELS,
2023-2030 (IN $ MILLION)
FIGURE 25: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY EYE
SOLUTIONS & SUSPENSIONS, 2023-2030 (IN $ MILLION)
FIGURE 26: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY CAPSULES
& TABLETS, 2023-2030 (IN $ MILLION)
FIGURE 27: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY EYE DROPS,
2023-2030 (IN $ MILLION)
FIGURE 28: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY OINTMENTS,
2023-2030 (IN $ MILLION)
FIGURE 29: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY CHANNEL,
2022 & 2030 (IN %)
FIGURE 30: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY HOSPITAL
PHARMACIES, 2023-2030 (IN $ MILLION)
FIGURE 31: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY DRUG
STORES, 2023-2030 (IN $ MILLION)
FIGURE 32: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY ONLINE
PHARMACIES, 2023-2030 (IN $ MILLION)
FIGURE 33: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY OTHER
CHANNELS, 2023-2030 (IN $ MILLION)
FIGURE 34: MIDDLE EAST AND AFRICA OPHTHALMIC DRUGS MARKET, BY COUNTRY
OUTLOOK, 2022 & 2030 (IN %)
FIGURE 35: UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $
MILLION)
FIGURE 36: TURKEY OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)
FIGURE 37: SAUDI ARABIA OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)
FIGURE 38: SOUTH AFRICA OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)
FIGURE 39: REST OF MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET,
2023-2030 (IN $ MILLION)